NCT04711863View on ClinicalTrials.gov

Fluvoxamine for Adults With Mild to Moderate COVID-19

PHASE2SuspendedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 16, 2021

Primary Completion Date

May 31, 2021

Study Completion Date

July 31, 2021

Conditions
Severe Acute Respiratory Syndrome Coronavirus 2Coronavirus InfectionMild to Moderate COVID-19
Interventions
DRUG

Fluvoxamine

Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days

DRUG

Placebo

Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT04711863 - Fluvoxamine for Adults With Mild to Moderate COVID-19 | Biotech Hunter | Biotech Hunter